Akiram Therapeutics AB
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Akiram Therapeutics AB - overview
Established
2021
Location
Uppsala, -, Sweden
Primary Industry
Medical Devices & Equipment
About
Founded in 2021 and based in Uppsala, Sweden, Akiram Therapeutics AB operates as a biotechnology company that develops radiopharmaceuticals and targeted radioimmunotherapy for the treatment of cancers like anaplastic thyroid cancer. Marika Nestor (CEO), Fredrik Frejd, and Anja Mortensen (CTO) are the co-founders of the company. In January 2023, Akiram Therapeutics AB raised SEK 68 million in venture funding from Sciety and Linc AB. The company focuses on the development of next-generation radiopharmaceuticals to specifically target and treat solid cancers.
Utilizing systemic targeted radiopharmaceuticals, the firm develops molecules that selectively deliver radioisotopes to tumors via the bloodstream, enabling visualization and eradication of cancer tissue. Akiram’s approach involves the use of targeted radioimmunotherapy that develops a unique antibody that guides radiation specifically to the tumor cells. The organization plans to use the January 2023 funding to develop novel radiotherapeutics for the treatment of hard-to-treat cancers, particularly thyroid cancer, and for the GMP production of its drug candidate.
Current Investors
Sciety, Linc AB
Primary Industry
Medical Devices & Equipment
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.akiramtherapeutics.se
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.